• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Braeburn raises $110m for opioid use disorder depot injection

January 11, 2018 By Sarah Faulkner

Braeburn PharmaceuticalsBraeburn Pharmaceuticals has raised $110 million in a mezzanine round of financing led by Wellington Capital. Other investors included Avista Capital Partners, RA Capital Management, Deerfield Management and Apple Tree Partners.

The Princeton, N.J.-based company said it plans to use the new funds to support the FDA approval process and commercialization of CAM2038, a weekly and monthly buprenorphine depot injection designed to treat adults with opioid use disorder.

“We are extremely pleased that this group of leading healthcare investors recognizes the potential of CAM2038, once approved, for which the FDA has granted priority review,” president & CEO, Mike Derkacz, said in prepared remarks.

“With opioid overdose now the leading cause of death among Americans under the age of 50, at Braeburn we are committed to playing our part by advancing new weekly and monthly medication-assisted treatments (MAT) to help support the recovery of people and their families devastated by opioid use disorder.”

Just 1.1 million of the 11.6 million people who misused opioids in the U.S. in 2016 received medication-assisted treatment, according to the Substance Abuse and Mental Health Services Administration.

“Consistent with FDA Commissioner Gottlieb’s recent statement encouraging wider, appropriate use of MAT for opioid addiction treatment, this financing further supports our efforts to expand treatment options by advancing CAM2038,” Derkacz added.

In September, the FDA granted priority review to Braeburn’s NDA for CAM2038. The agency is slated to decide whether it will approve or reject the product’s application by Jan. 19.

The subcutaneous injection is set to be offered in dosage strengths for once-weekly and once-monthly administration in pre-filled syringes.

CAM2038’s NDA included positive results from a pivotal Phase III trial, demonstrating non-inferiority versus treatment with the current standard of care – a daily sublingual buprenorphine/naloxone product.

Braeburn’s depot also had a safety profile that was consistent with the known safety profile of buprenorphine, except for some mild-to-moderate adverse events at the injection site.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Regulatory/Compliance Tagged With: Braeburn Pharmaceuticals

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS